NDA 020338 · Galderma Labs Lp
Differin
Adapalene · Topical
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Apr 8, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
May 31, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
112
28 Phase 3, 7 recruiting
FAERS reports
6,328
864 serious, 25 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 31, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- DIFFERIN · ADAPALENE 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Adapalene" as an intervention, any sponsor and status, largest first.
- Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01742637 · 2,008 participants · Start Oct 2012 · Primary completion Feb 2014
Drug: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%; Epiduo® Gel and 1 more · For: Acne Vulgaris
- A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT00421993 · 1,670 participants · Start Oct 2006 · Primary completion Oct 2007
Drug: Adapalene/Benzoyl Peroxide; Adapalene and 2 more · For: Acne Vulgaris
Sites: Huntsville, Alabama; Little Rock, Arkansas; Fresno, California · 62 sites in all
- Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT00422240 · 1,668 participants · Start Jun 27, 2006 · Primary completion Jul 12, 2007
Drug: Adapalene/Benzoyl Peroxide; Adapalene Gel, 0.1% and 2 more · For: Acne Vulgaris
Sites: San Antonio, Texas
- A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne VulgarisPivotal-lookingCompleted
Lee's Pharmaceutical LimitedIndustry
NCT03615768 · 1,617 participants · Start Aug 14, 2018 · Primary completion Feb 13, 2020
Drug: Adapalene Gel; Clindamycin Gel · For: Acne Vulgaris
Sites: Nanjing, China
- Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical GelPivotal-lookingCompleted
Actavis Mid-Atlantic LLCIndustry
NCT01095640 · 1,159 participants · Start Mar 2009 · Primary completion Dec 2009
Drug: adapalene 0.3% topical gel · For: Acne Vulgaris
Sites: Mumbai, India
- Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%Pivotal-lookingCompleted
Galderma R&DIndustry
NCT00598832 · 1,075 participants · Start Nov 2007 · Primary completion Oct 2008
Drug: Adapalene lotion 0.1%; Adapalene Lotion Vehicle · For: Acne Vulgaris
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; Marina del Rey, California · 34 sites in all
- Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%Pivotal-lookingCompleted
Galderma R&DIndustry
NCT00599521 · 1,067 participants · Start Nov 2007 · Primary completion Nov 2008
Drug: Adapalene lotion 0.1%; Adapalene Lotion Vehicle · For: Acne Vulgaris
Sites: San Diego, California; Vista, California; Denver, Colorado · 34 sites in all
- Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne VulgarisPivotal-lookingCompleted
Actavis Inc.Industry
NCT02651220 · 1,001 participants · Start Nov 2015 · Primary completion Apr 2016
Drug: Epiduo® Forte Gel; Adapalene and Benzoyl Peroxide Gel and 1 more · For: Acne
Sites: Mesa, Arizona; Tucson, Arizona; Anaheim, California · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,537
- dry skin941
- skin burning sensation574
- acne553
- skin irritation535
- erythema504
- condition aggravated442
- rash405
- skin exfoliation352
- therapy cessation227
- pruritus205
- hypersensitivity182
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 12 |
| 2006 | 26 |
| 2007 | 9 |
| 2008 | 28 |
| 2009 | 26 |
| 2010 | 33 |
| 2011 | 78 |
| 2012 | 62 |
| 2013 | 58 |
| 2014 | 71 |
| 2015 | 118 |
| 2016 | 118 |
| 2017 | 72 |
| 2018 | 82 |
| 2019 | 175 |
| 2020 | 128 |
| 2021 | 108 |
| 2022 | 155 |
| 2023 | 195 |
| 2024 | 832 |
| 2025 | 878 |
| 2026 | 3,051 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Differin (Adapalene)
2024 spending
$58K
Beneficiaries
77
124 claims
Per beneficiary
$748
$9.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $140,908 |
| 2021 | $123,488 |
| 2022 | $111,263 |
| 2023 | $93,764 |
| 2024 | $57,572 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Perioral dermatitis: Diagnosis, proposed etiologies, and management.
Searle T, Ali FR, Al-Niaimi F · J Cosmet Dermatol 2021 · Systematic Review
- Topical Retinoids in Acne Vulgaris: A Systematic Review.
Kolli SS, Pecone D, Pona A, et al. · Am J Clin Dermatol 2019 · Systematic Review
- Acne vulgaris.
Purdy S, de Berker D · BMJ Clin Evid 2011 · Systematic Review
- Acne vulgaris.
Purdy S, Deberker D · BMJ Clin Evid 2008 · Systematic Review
- Spotlight on adapalene.
Piérard GE, Piérard-Franchimont C, Paquet P, et al. · Expert Opin Drug Metab Toxicol 2009 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Galderma Labs Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.